2nd Quarter - Report

THE LIVINGSTON GROUP, LLC for PKD FOUNDATION

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Provide for research and clinical funding for PKD under the competitive Defense Peer Reviewed Medical Research Program under the FY 2009 Defense Appropriations bill (H.R. 3222 and Senate counterpart to be introduced); PKD report language to establish PKD Clinical and Diagnostic Treatment Centers in the NIH/NIDDK section of FY09 LHHS Approps bill (HR 3043:S. 1710); language to fund the expansion of PKD-specific patient services, education and empowerment initiatives that will support patient education, disease management and outreach in the HHS section of the FY 2009 Labor/HHS/Education Appropriations bill (H.R. 3043, S. 1710); passage of the entire Genetic Information Nondiscrimination Act of 2008 (HR 493; S 358); National PKD Awareness Week Resolution for 2008 to be introduced in the Senate; expansion of immunosuppressive drug coverage through the passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 (HR 3282, S 2030); passage of the entire Kidney Care Quality and Education Act of 2007 (HR 1193, S 691).

LobbyistCovered position, as disclosed
ROBERT L LIVINGSTON Former Rep., US House
J ALLEN MARTIN Former COS, Cong. Livingston

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1710 (110th), H.R. 3043 (110th), H.R. 3282 (110th), H.R. 493 (110th), H.R. 3222 (110th), H.R. 1193 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.